THE CLINICAL TRIAL
Decompensated cirrhosis is defined as an acute deterioration in liver function in a patient with cirrhosis and is characterized by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome or variceal haemorrhage. The purpose of the Red-C Studies was to see if an investigational drug given twice daily, will help delay the first episode of overt hepatic encephalopathy requiring hospitalization in patients with liver cirrhosis and how safe it is to use in people.
Bausch Health and PRA Health Sciences goal was to accelerate recruitment for this clinical study using a suite of patient recruitment materials developed by the Stark / Raving team. The program consisted of two global clinical studies, each with specific recruitment criteria. Our approach focused on establishing a unique study brand identity combined with recruitment and educational materials that engaged and empowered patients to consider participation.